Ronald Muhlenkamp
Muhlenkamp & Co
Ronald Muhlenkamp Pfizer Inc stake
total: 197
Muhlenkamp & Co PFE trades
- Total transactions:
- 25
- New positions:
- 1
- Sold out:
- 1
- Added:
- 4
- Reduced:
- 19
- Held since:
- 2013 Q2 or earlier
- Held for:
- 35+ quarters
- Latest activity:
- 2022 Q3
According to 2026 Q2 report, Ronald Muhlenkamp doesn't hold any Pfizer Inc (PFE) shares. Muhlenkamp & Co has held PFE since at least 2013 Q2 with 36,364 shares in our earliest available record. Since at least 2013 Q2, Muhlenkamp & Co has made 24 more transactions.
When did Ronald Muhlenkamp sell Pfizer Inc (PFE)?
Ronald Muhlenkamp sold off the entire Pfizer Inc (PFE) position in 2022 Q3.
Estimated cost basis*
- Weighted AVG buy price:
- $28.96
- Weighted AVG sell price:
- $43.51
Ronald Muhlenkamp's historical trades in Pfizer Inc
25 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2022 Q3
|
0.00%
|
0
|
$52.43
|
|
-100% (-24,164)
|
-0.59%
|
|
2022 Q2
|
0.59%
|
24,164
|
$52.43
|
$1,267,000
|
-0.88% (-215)
|
-0%
|
|
2021 Q1
|
0.45%
|
24,379
|
$50.41
|
$1,229,000
|
+2.70% (+640)
|
+0.01%
|
|
2020 Q4
|
0.35%
|
$36.82
|
-0.12% (-28)
|
|||
|
2020 Q3
|
0.45%
|
$36.69
|
-0.65% (-155)
|
|||
|
2020 Q2
|
0.42%
|
$32.69
|
-4.37% (-1,092)
|
|||
|
2019 Q4
|
0.43%
|
$39.18
|
-2.63% (-675)
|
|||
|
2019 Q3
|
0.45%
|
$35.93
|
-0.37% (-96)
|
|||
|
2019 Q2
|
0.54%
|
$43.32
|
+0.39% (+100)
|
|||
|
2019 Q1
|
0.52%
|
$42.48
|
-2.82% (-745)
|
|||
|
2018 Q3
|
0.50%
|
$44.08
|
-3.84% (-1,055)
|
|||
|
2018 Q2
|
0.38%
|
$36.27
|
+0.90% (+246)
|
|||
|
2018 Q1
|
0.35%
|
$35.50
|
-0.93% (-255)
|
|||
|
2017 Q3
|
0.33%
|
$35.72
|
-16.77% (-5,540)
|
|||
|
2017 Q1
|
0.37%
|
$34.21
|
-2.80% (-950)
|
|||
|
2016 Q4
|
0.37%
|
$32.49
|
-5.69% (-2,050)
|
|||
|
2016 Q3
|
0.47%
|
$33.86
|
-2.74% (-1,015)
|
|||
|
2016 Q2
|
0.51%
|
$35.20
|
-3.54% (-1,360)
|
|||
|
2014 Q4
|
0.24%
|
$31.14
|
-2.76% (-1,090)
|
|||
|
2014 Q3
|
0.21%
|
$29.57
|
-3.71% (-1,520)
|
|||
|
2014 Q2
|
0.22%
|
$29.67
|
-0.36% (-150)
|
|||
|
2014 Q1
|
0.23%
|
$32.11
|
-8.77% (-3,960)
|
|||
|
2013 Q4
|
0.25%
|
$30.62
|
+29.15% (+10,185)
|
|||
|
2013 Q3
|
0.20%
|
$28.73
|
-3.90% (-1,420)
|
|||
|
2013 Q2
|
0.21%
|
$28.02
|
new or own*
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.